Date published: 2025-12-19

1-800-457-3801

SCBT Portrait Logo
Seach Input

c-Mpl Activators

c-Mpl activators represent a class of chemical compounds that interact specifically with the cellular receptor known as c-Mpl, also referred to as the thrombopoietin receptor (TPO-R). This receptor is a member of the type I cytokine receptor family and is primarily involved in the regulation of hematopoietic processes, especially in megakaryocyte and platelet production. The c-Mpl receptor is a transmembrane protein that, upon activation, initiates a cascade of intracellular signaling pathways. These pathways predominantly involve the Janus kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) axis, among other downstream signaling molecules. The activation of these pathways leads to changes in gene expression that drive cell proliferation, differentiation, and survival. Importantly, c-Mpl activators are not limited to proteins like thrombopoietin; small molecule activators and peptide mimetics have also been identified, which can effectively modulate the receptor's activity.The structural diversity of c-Mpl activators is broad, encompassing both natural ligands like thrombopoietin and synthetic molecules designed to mimic or enhance the receptor's activation. These activators typically engage the receptor by binding to its extracellular domain, inducing conformational changes that propagate through the transmembrane domain to the intracellular signaling regions. The precise mechanism by which these activators modulate the receptor function can vary; some may induce full activation of the receptor, while others may act as partial agonists, selectively triggering certain signaling pathways over others. Additionally, research into c-Mpl activators has revealed insights into the receptor's structural biology, offering a deeper understanding of how ligand binding translates into specific cellular responses. This knowledge has implications for studying how signal transduction is regulated within hematopoietic cells, providing a basis for exploring the fundamental biological roles of c-Mpl in various physiological processes.

Items 1 to 10 of 13 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Eltrombopag

496775-61-2sc-207614
sc-207614A
sc-207614B
5 mg
50 mg
100 mg
$263.00
$381.00
$490.00
1
(0)

Eltrombopag acts as a potent c-mpl receptor agonist, engaging in specific molecular interactions that enhance thrombopoietin signaling. By stabilizing the receptor's active conformation, it promotes the recruitment of downstream signaling molecules, thereby amplifying the JAK-STAT pathway. This modulation of receptor dynamics influences gene expression related to hematopoiesis, showcasing its role in fine-tuning cellular responses within the hematopoietic niche.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

5-Azacytidine could downregulate c-Mpl by inducing demethylation of its gene promoter, which might silence gene expression.

5-Aza-2′-Deoxycytidine

2353-33-5sc-202424
sc-202424A
sc-202424B
25 mg
100 mg
250 mg
$214.00
$316.00
$418.00
7
(1)

5-Aza-2′-Deoxycytidine (Decitabine) may decrease c-Mpl levels by specifically targeting hypermethylated CpG islands within the MPL gene, leading to transcriptional inactivation.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid (Vorinostat) is hypothesized to reduce c-Mpl expression by preventing deacetylation of histones, thus maintaining a chromatin structure not conducive to gene transcription.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A may decrease c-Mpl expression through the inhibition of histone deacetylases, resulting in a histone acetylation pattern that represses the MPL gene.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

Retinoic acid could reduce c-Mpl expression by binding to retinoic acid receptors that heterodimerize with repressor proteins at the MPL gene's regulatory regions.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin might inhibit c-Mpl expression by halting the mTOR signaling pathway, which is essential for the translation of certain transcripts including those related to c-Mpl.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is thought to decrease c-Mpl levels by blocking PI3K, an upstream activator of AKT signaling, which is critical for the transcription of growth-related genes.

Bromocriptine

25614-03-3sc-337602A
sc-337602B
sc-337602
10 mg
100 mg
1 g
$56.00
$260.00
$556.00
4
(1)

This dopamine agonist has been investigated for its potential to activate c-Mpl and stimulate platelet production, particularly in cases of thrombocytopenia.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 could inhibit c-Mpl expression by preventing JNK-mediated phosphorylation of transcription factors that directly promote the MPL gene's transcription.